Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

By T. André, C. Boni, M. Navarro, J. Tabernero, T. Hickish, C. Topham, A. Bonetti, P. Clingan, J. Bridgewater, F. Rivera and 1 more. Journal of Clinical Oncology, 2009

2,136 citations recorded by the source corpus.

Subfields: Hepatology, Oncology

View Paper: https://www.semanticscholar.org/paper/037ec0de81994c4e5edf94d736d025133d72badf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Yothers
2. G. Argilés
3. Toshiaki Watanabe
4. M. O’connell
5. C. Allegra
6. A. Cervantes
7. J. Tabernero
8. G. Beretta

Citations in the corpus

• Chemotherapy‐induced peripheral neurotoxicity: A critical analysis (2013, methodology): “The most common symptoms are distal limb and mouth paresthesias exacerbated by cold exposure, jaw pain on biting, and mouth numbness.(136,137) Motor signs and symptoms may also occur, including muscular spasm-like contractions, fasciculations, and cramps.”
• Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, result): “It is also felt by the panel members that patients with high risk, patients with pT4 and/or <12 lymph nodes or accumulation of several intermediate risk factors, might be considered for the addition of oxaliplatin therapy based on a trend to an increased benefit, although this did not achieve statis”
• Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, background): “The update at the 6-year follow-up confirmed the benefit in DFS of adjuvant treatment with FOLFOX4, and an advantage was also observed in overall survival (OS), but for stage III patients only [30].”
• Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, background): “• Randomized controlled trials conducted in Europe and the United States have shown that the combination of intravenous infusion of 5-FU ? LV and L-OHP (FOLFOX4 and FLOX) used as postoperative adjuvant chemotherapy for stage III colon cancer provides an additional benefit in terms of prevention of r”
• Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. (2011, background): “1% improvement in 6-year OS.(3) Considering the added toxicity associated with oxaliplatin treatment, the risk:benefit ratio with this agent is likely unfavorable for most patients with stage II colon cancer.”